skip to Main Content

Local Scientific Fellow presenting at International Conference

Dr Brenda Castro, Scientific Fellow, LVF Ophthalmology Research Centre presented a poster at the XXV Biennial Meeting of the International Society for Eye Research (ISER), Gold Coast on 19-23 February 2023.

The International Society for Eye Research (ISER), provides a unique international platform for discussion and exchange of ideas on contemporary topics in eye and vision research among its members and the broader eye/vision research community. The scientific program provides a unique platform for presentations and discussions on advancing scientific research, at both clinical and laboratory levels.

The poster Dr Castro presented included data regarding the development of a gene therapy employing a vector optimised for retinal gene delivery. This can lead to lower doses and lesser adverse events, increasing the safety. It also included some elements for a controlled expression of the therapeutic protein, which also improves safety and allows for an individualised treatment.

The Poster Topic:

Engineered AAV Capsids and Inducible Systems as Strategies for an Optimised Gene Therapy Targeting Acquired Retinal Diseases

Acknowledgement of the Contributors:

Brenda F. M. Castro*1,2, Sergei Kozlov1,2, Jason C. Steel3, Christopher J. Layton1,2,3,

  1. LVF Ophthalmology Research Centre, Translational Research Institute, Woolloongabba, QLD 4102, Australia
  2. Greenslopes Clinical School, University of Queensland School of Medicine, Brisbane, Australia
  3. School of Health, Medical and Applied Sciences, Central Queensland University, Queensland, Australia

Aim:

Development of optimised gene therapies for acquired ocular conditions by employing AAV variants with enhanced retinal tropism and constructs containing inducible systems, in order to achieve a targeted and regulated expression.

Conclusion:

A novel AAV variant with optimised retinal tropism for intravitreal application was developed along with constructs allowing a controlled expression to improve the potential application of gene therapies in acquired ocular diseases.

Back To Top